Primary Prevention of Type 2 Diabetes Mellitus in the European Union: A Systematic Review of Interventional Studies
Abstract
:1. Introduction
2. Materials and Methods
2.1. PICOs and Research Question
- Population: individuals of all age groups without DM living in the 28 member states of the EU.
- Intervention: we aimed to analyze a wide range of interventions related to physical activity regimen, dietary modifications, weight management programs, eating patterns, counseling sessions, change in attitudes, knowledge gain, supplement intake, glycemia monitoring protocols, and other preventive measures to reduce the incidence of T2D.
- Control: each intervention was compared with a control group, which could be the absence of the intervention, conventional treatments, or varying levels of the same intervention.
- Outcomes: the primary outcome measure was the incidence of T2D.
- Types of study: only interventional studies were considered for inclusion in our analysis, including but not limited to randomized clinical trials (RCTs), non-randomized trials, quasi-experimental studies, and clinical trials.
- Among individuals without DM residing in the EU-28, what is the effectiveness of preventive interventions compared to standard care in reducing the incidence of T2D?
- How do different preventive measures targeting nondiabetic populations in the EU-28, such as weight loss programs, dietary supplements, counseling, physical activity, or exercise regimens, compare in terms of their ability to lower the incidence of T2D?
2.2. Eligibility Criteria
2.3. Search Strategy, Study Selection, and Data Extraction
2.4. Methodological Quality Assessment and Data Analysis
- Low Methodological Quality:
- ◦
- Critical domain questions: One or more “no” answers, or one “no” answer combined with one “cannot determine/not reported”, or two or more “cannot determine/not reported” answers.
- ◦
- Non-critical domain questions: Three or more “no” answers, or four or more “cannot determine/not reported”, or one “cannot determine/not reported” response combined with two “no” answers.
- Moderate Methodological Quality:
- ◦
- Critical domain questions: One “no” answer and one “cannot determine/not reported” answer.
- ◦
- Non-critical domain questions: Two “no” answers, or three “cannot determine/not reported”, or one “cannot determine/not reported” response combined with one “no” answer.
- High Methodological Quality:
- ◦
- Critical domain questions: No “no” answers and no “cannot determine/not reported”.
- ◦
- Non-critical domain questions: One “no” answer and at most two “cannot determine/not reported” responses.
3. Results
Characteristics of the Included Studies
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Data Availability Statement
Conflicts of Interest
References
- European Commission. Knowledge for Policy: Health Promotion and Disease Prevention Knowledge Gateway. Diabetes preventions. 2021. Available online: https://knowledge4policy.ec.europa.eu/health-promotion-knowledge-gateway/diabetes-prevention_en (accessed on 12 June 2024).
- International Diabetes Federation. IDF Diabetes Atlas, 10th ed.; International Diabetes Federation: Brussels, Belgium, 2021; Available online: https://diabetesatlas.org/idfawp/resource-files/2021/07/IDF_Atlas_10th_Edition_2021.pdf (accessed on 12 June 2024).
- European Union. Health at a Glance: Europe 2020: State of Health in the EU Cycle; OECD Publishing: Paris, France, 2020. [Google Scholar] [CrossRef]
- Health and Environment Alliance (HEAL). Health Costs in the European Union—How Much Is Related to EDCS; Health and Environment Alliance (HEAL): Brussels, Belgium, 2014; Available online: https://www.env-health.org/IMG/pdf/18062014_final_health_costs_in_the_european_union_how_much_is_realted_to_edcs.pdf (accessed on 12 June 2024).
- Khan, M.A.B.; Hashim, M.J.; King, J.K.; Govender, R.D.; Mustafa, H.; Al Kaabi, J. Epidemiology of Type 2 Diabetes—Global Burden of Disease and Forecasted Trends. J. Epidemiol. Glob. Health 2020, 10, 107–111. [Google Scholar] [CrossRef]
- World Health Organization. Global Report on Diabetes; World Health Organization: Geneva, Switzerland, 2016; Available online: https://iris.who.int/handle/10665/204871 (accessed on 12 June 2024).
- Skoglund, G.; Nilsson, B.B.; Olsen, C.F.; Bergland, A.; Hilde, G. Facilitators and barriers for lifestyle change in people with prediabetes: A meta-synthesis of qualitative studies. BMC Public Health 2022, 22, 553. [Google Scholar] [CrossRef]
- Nikpour, S.; Mehrdad, N.; Sanjari, M.; Aalaa, M.; Heshmat, R.; Mafinejad, M.K.; Larijani, B.; Nomali, M.; Ghezeljeh, T.N. Challenges of Type 2 Diabetes Mellitus Management From the Perspective of Patients: Conventional Content Analysis. Interact. J. Med. Res. 2022, 11, e41933. [Google Scholar] [CrossRef]
- Mahrouseh, N.; Lovas, S.; Njuguna, D.W.; Nellamkuzhi, N.J.; Soares Andrade, C.A.; Sackey, W.E.; Irawan, A.S.; Varga, O. How the European Union legislations are tackling the burden of diabetes mellitus: A legal surveillance study. Front. Public Health 2022, 10, 1002265. [Google Scholar] [CrossRef]
- European Parliament. European Parliament resolution of 23 November 2022 on Prevention, Management and Better Care of Diabetes in the EU on the Occasion of World Diabetes Day. Available online: https://www.europarl.europa.eu/doceo/document/TA-9-2022-0409_EN.html (accessed on 12 June 2024).
- International Diabetes Federation European Region. Diabetes—The Policy Puzzle: Towards Benchmarking in the EU 25. Available online: https://health.ec.europa.eu/system/files/2016-11/policy_puzzle_benchmarking_eu25_0.pdf (accessed on 12 June 2024).
- Manios, Y.; Lambrinou, C.P.; Mavrogianni, C.; Cardon, G.; Lindström, J.; Iotova, V.; Tankova, T.; Rurik, I.; Stappen, V.V.; Kivelä, J.; et al. Lifestyle Changes Observed among Adults Participating in a Family- and Community-Based Intervention for Diabetes Prevention in Europe: The 1st Year Results of the Feel4Diabetes-Study. Nutrients 2020, 12, 1949. [Google Scholar] [CrossRef]
- OECD. Healthy Eating and Active Lifestyles: Best Practices in Public Health; OECD: Paris, France, 2022. [Google Scholar] [CrossRef]
- Tuomilehto, J.; Uusitupa, M.; Gregg, E.W.; Lindström, J. Type 2 Diabetes Prevention Programs—From Proof-of-Concept Trials to National Intervention and Beyond. J. Clin. Med. 2023, 12, 1876. [Google Scholar] [CrossRef]
- Tuomilehto, J.; Lindström, J.; Eriksson, J.G.; Valle, T.T.; Hämäläinen, H.; Ilanne-Parikka, P.; Keinänen-Kiukaanniemi, S.; Laakso, M.; Louheranta, A.; Rastas, M.; et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N. Engl. J. Med. 2001, 344, 1343–1350. [Google Scholar] [CrossRef]
- NHLBI. Study Quality Assessment Tools. Available online: https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools (accessed on 12 June 2024).
- Skaaby, T.; Jørgensen, T.; Linneberg, A. A randomized general population study of the effects of repeated health checks on incident diabetes. Endocrine 2018, 60, 122–128. [Google Scholar] [CrossRef]
- Lindström, J.; Eriksson, J.G.; Valle, T.T.; Aunola, S.; Cepaitis, Z.; Hakumäki, M.; Hämäläinen, H.; Ilanne-Parikka, P.; Keinänen-Kiukaanniemi, S.; Laakso, M.; et al. Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: Results from a randomized clinical trial. J. Am. Soc. Nephrol. 2003, 14 (Suppl. 2), S108–S113. [Google Scholar] [CrossRef]
- Lindström, J.; Ilanne-Parikka, P.; Peltonen, M.; Aunola, S.; Eriksson, J.G.; Hemiö, K.; Hämäläinen, H.; Härkönen, P.; Keinänen-Kiukaanniemi, S.; Laakso, M.; et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: Follow-up of the Finnish Diabetes Prevention Study. Lancet Lond. Engl. 2006, 368, 1673–1679. [Google Scholar] [CrossRef]
- Lindström, J.; Peltonen, M.; Eriksson, J.G.; Ilanne-Parikka, P.; Aunola, S.; Keinänen-Kiukaanniemi, S.; Uusitupa, M.; Tuomilehto, J.; Finnish Diabetes Prevention Study (DPS). Improved lifestyle and decreased diabetes risk over 13 years: Long-term follow-up of the randomised Finnish Diabetes Prevention Study (DPS). Diabetologia 2013, 56, 284–293. [Google Scholar] [CrossRef]
- Salas-Salvadó, J.; Bulló, M.; Babio, N.; Martínez-González, M.Á.; Ibarrola-Jurado, N.; Basora, J.; Estruch, R.; Covas, M.I.; Corella, D.; Arós, F.; et al. Reduction in the incidence of type 2 diabetes with the Mediterranean diet: Results of the PREDIMED-Reus nutrition intervention randomized trial. Diabetes Care 2011, 34, 14–19. [Google Scholar] [CrossRef]
- Costa, B.; Barrio, F.; Cabré, J.J.; Piñol, J.L.; Cos, X.; Solé, C.; Bolíbar, B.; Basora, J.; Castell, C.; Solà-Morales, O.; et al. Delaying progression to type 2 diabetes among high-risk Spanish individuals is feasible in real-life primary healthcare settings using intensive lifestyle intervention. Diabetologia 2012, 55, 1319–1328. [Google Scholar] [CrossRef]
- Salas-Salvadó, J.; Bulló, M.; Estruch, R.; Ros, E.; Covas, M.I.; Ibarrola-Jurado, N.; Corella, D.; Arós, F.; Gómez-Gracia, E.; Ruiz-Gutiérrez, V.; et al. Prevention of diabetes with Mediterranean diets: A subgroup analysis of a randomized trial. Ann. Intern. Med. 2014, 160, 1–10. [Google Scholar] [CrossRef]
- Sanchez, A.; Silvestre, C.; Campo, N.; Grandes, G.; PredDE Group. Effective translation of a type-2 diabetes primary prevention programme into routine primary care: The PreDE cluster randomised clinical trial. Diabetes Res. Clin. Pract. 2018, 139, 32–42. [Google Scholar] [CrossRef]
- de la Cruz-Ares, S.; Gutiérrez-Mariscal, F.M.; Alcalá-Díaz, J.F.; Quintana-Navarro, G.M.; Podadera-Herreros, A.; Cardelo, M.P.; Torres-Peña, J.D.; Arenas-de Larriva, A.P.; Pérez-Martínez, P.; Delgado-Lista, J.; et al. Quality and Quantity of Protein Intake Influence Incidence of Type 2 Diabetes Mellitus in Coronary Heart Disease Patients: From the CORDIOPREV Study. Nutrients 2021, 13, 1217. [Google Scholar] [CrossRef]
- Penn, L.; White, M.; Oldroyd, J.; Walker, M.; Alberti, K.G.M.; Mathers, J.C. Prevention of type 2 diabetes in adults with impaired glucose tolerance: The European Diabetes Prevention RCT in Newcastle upon Tyne, UK. BMC Public Health 2009, 9, 342. [Google Scholar] [CrossRef]
- Bhopal, R.S.; Douglas, A.; Wallia, S.; Forbes, J.F.; Lean, M.E.; Gill, J.M.; McKnight, J.A.; Sattar, N.; Sheikh, A.; Wild, S.H.; et al. Effect of a lifestyle intervention on weight change in south Asian individuals in the UK at high risk of type 2 diabetes: A family-cluster randomised controlled trial. Lancet Diabetes Endocrinol. 2014, 2, 218–227. [Google Scholar] [CrossRef]
- Davies, M.J.; Gray, L.J.; Troughton, J.; Gray, A.; Tuomilehto, J.; Farooqi, A.; Khunti, K.; Yates, T.; Let’s Prevent Diabetes Team. A community based primary prevention programme for type 2 diabetes integrating identification and lifestyle intervention for prevention: The Let’s Prevent Diabetes cluster randomised controlled trial. Prev. Med. 2016, 84, 48–56. [Google Scholar] [CrossRef]
- Nanditha, A.; Thomson, H.; Susairaj, P.; Srivanichakorn, W.; Oliver, N.; Godsland, I.F.; Majeed, A.; Darzi, A.; Satheesh, K.; Simon, M.; et al. A pragmatic and scalable strategy using mobile technology to promote sustained lifestyle changes to prevent type 2 diabetes in India and the UK: A randomised controlled trial. Diabetologia 2020, 63, 486–496. [Google Scholar] [CrossRef]
- Sampson, M.; Clark, A.; Bachmann, M.; Garner, N.; Irvine, L.; Howe, A.; Greaves, C.; Auckland, S.; Smith, J.; Turner, J.; et al. Lifestyle Intervention with or Without Lay Volunteers to Prevent Type 2 Diabetes in People with Impaired Fasting Glucose and/or Nondiabetic Hyperglycemia: A Randomized Clinical Trial. JAMA Intern. Med. 2021, 181, 168–178. [Google Scholar] [CrossRef]
- Roumen, C.; Feskens, E.J.M.; Corpeleijn, E.; Mensink, M.; Saris, W.H.M.; Blaak, E.E. Predictors of lifestyle intervention outcome and dropout: The SLIM study. Eur. J. Clin. Nutr. 2011, 65, 1141–1147. [Google Scholar] [CrossRef]
- Vermunt, P.W.A.; Milder, I.E.J.; Wielaard, F.; de Vries, J.H.; Baan, C.A.; van Oers, J.A.; Westert, G.P. A lifestyle intervention to reduce Type 2 diabetes risk in Dutch primary care: 2.5-year results of a randomized controlled trial. Diabet. Med. 2012, 29, e223–e231. [Google Scholar] [CrossRef]
- McHugh, M.L. Interrater reliability: The kappa statistic. Biochem. Medica 2012, 22, 276–282. [Google Scholar] [CrossRef]
- World Health Organization. Department of Noncommunicable Disease Surveillance. Definition, Diagnosis, and Classification of Diabetes Mellitus. Part 1: Diagnosis and Classification of Diabetes Mellitus; WHO: Geneva, Switzerland, 1999; Available online: https://iris.who.int/bitstream/handle/10665/66040/WHO_NCD_NCS_99.2.pdf?sequence=1 (accessed on 10 March 2025).
- World Health Organization. Use of Glycated Haemoglobin (HbA1c) in the Diagnosis of Diabetes Mellitus; WHO: Geneva, Switzerland, 2011; Available online: https://iris.who.int/bitstream/handle/10665/70523/WHO_NMH_CHP_CPM_11.1_eng.pdf (accessed on 10 March 2025).
- Gumber, A.; Gumber, L. Improving prevention, monitoring and management of diabetes among ethnic minorities: Contextualizing the six G’s approach. BMC Res. Notes 2017, 10, 774. [Google Scholar] [CrossRef]
- Michels, K.B. The promise and challenges of population strategies of prevention. Int. J. Epidemiol. 2008, 37, 914–916. [Google Scholar] [CrossRef]
- Platt, J.M.; Keyes, K.M.; Galea, S. Efficiency or equity? Simulating the impact of high-risk and population intervention strategies for the prevention of disease. SSM-Popul. Health 2017, 3, 1–8. [Google Scholar] [CrossRef]
- Goveia, P.; Cañon-Montañez, W.; Santos, D.P.; Lopes, G.W.; Ma, R.C.W.; Duncan, B.B.; Ziegelman, P.K.; Schmidt, M.I. Lifestyle Intervention for the Prevention of Diabetes in Women With Previous Gestational Diabetes Mellitus: A Systematic Review and Meta-Analysis. Front. Endocrinol. 2018, 9, 583. [Google Scholar] [CrossRef]
- Knowler, W.C.; Barrett-Connor, E.; Fowler, S.E.; Hamman, R.F.; Lachin, J.M.; Walker, E.A.; Nathan, D.M.; Diabetes Prevention Program Research Group. Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin. N. Engl. J. Med. 2002, 346, 393–403. [Google Scholar] [CrossRef]
- Karamanakos, G.; Costa-Pinel, B.; Gilis-Januszewska, A.; Velickiene, D.; Barrio-Torrell, F.; Cos-Claramunt, X.; Mestre-Miravet, S.; Piwońska-Solska, B.; Hubalewska-Dydejczyk, A.; Tuomilehto, J.; et al. The effectiveness of a community-based, type 2 diabetes prevention programme on health-related quality of life. The DE-PLAN study. PLoS ONE 2019, 14, e0221467. [Google Scholar] [CrossRef]
- Shirvani, T.; Javadivala, Z.; Azimi, S.; Shaghaghi, A.; Fathifar, Z.; Devender Bhalla, H.D.R.; Abdekhoda, M.; Nadrian, H. Community-based educational interventions for prevention of type II diabetes: A global systematic review and meta-analysis. Syst. Rev. 2021, 10, 81. [Google Scholar] [CrossRef]
- Dineen, T.E.; Bean, C.; Jung, M.E. Implementation of a diabetes prevention program within two community sites: A qualitative assessment. Implement. Sci. Commun. 2022, 3, 11. [Google Scholar] [CrossRef]
- Aziz, Z.; Absetz, P.; Oldroyd, J.; Pronk, N.P.; Oldenburg, B. A systematic review of real-world diabetes prevention programs: Learnings from the last 15 years. Implement. Sci. 2015, 10, 172. [Google Scholar] [CrossRef]
- Teoh, K.W.; Ng, C.M.; Chong, C.W.; Bell, J.S.; Cheong, W.L.; Lee, S.W.H. Knowledge, attitude, and practice toward pre-diabetes among the public, patients with pre-diabetes and healthcare professionals: A systematic review. BMJ Open Diabetes Res. Care 2023, 11, e003203. [Google Scholar] [CrossRef]
- de Jong, M.; Jansen, N.; van Middelkoop, M. A systematic review of patient barriers and facilitators for implementing lifestyle interventions targeting weight loss in primary care. Obes. Rev. Off. J. Int. Assoc. Study Obes. 2023, 24, e13571. [Google Scholar] [CrossRef]
- Aziz, Z.; Riddell, M.A.; Absetz, P.; Brand, M.; Oldenburg, B.; Australasian Peers for Progress Diabetes Project Investigators. Peer support to improve diabetes care: An implementation evaluation of the Australasian Peers for Progress Diabetes Program. BMC Public Health 2018, 18, 262. [Google Scholar] [CrossRef]
- Iqbal, N. The burden of type 2 diabetes: Strategies to prevent or delay onset. Vasc. Health Risk Manag. 2007, 3, 511–520. [Google Scholar]
- Prevention or Delay of Type 2 Diabetes: Standards of Medical Care in Diabetes—2021|Diabetes Care|American Diabetes Association. Available online: https://diabetesjournals.org/care/article/44/Supplement_1/S34/30895/3-Prevention-or-Delay-of-Type-2-Diabetes-Standards (accessed on 12 June 2024).
- Beck, J.; Greenwood, D.A.; Blanton, L.; Bollinger, S.T.; Butcher, M.K.; Condon, J.E.; Cypress, M.; Faulkner, P.; Fischl, A.H.; Francis, T.; et al. 2017 National Standards for Diabetes Self-Management Education and Support. Diabetes Educ. 2017, 43, 449–464. [Google Scholar] [CrossRef]
- ElSayed, N.A.; Aleppo, G.; Aroda, V.R.; Bannuru, R.R.; Brown, F.M.; Bruemmer, D.; Collins, B.S.; Hilliard, M.E.; Isaacs, D.; Johnson, E.L.; et al. 2. Classification and Diagnosis of Diabetes: Standards of Care in Diabetes—2023. Diabetes Care 2022, 46 (Suppl. S1), S19–S40. [Google Scholar] [CrossRef]
Title | Author (Year) | Country | City or Region | Study Design | Sample (n) | Male (n) | Female (n) | Total Sample Age Range | Follow-Up Time |
---|---|---|---|---|---|---|---|---|---|
A randomized general population study of the effects of repeated health checks on incident diabetes | Skaaby et al. (2018) [17] | Denmark | Suburbs of Copenhagen | Randomized trial (pre-randomized allocation of participants) | 17,631 Control: 12,892 Intervention: 4739 | 8700 Control: 6333 Intervention: 2367 | 8931 Control: 6559 Intervention: 2372 | 30 to 60 years old | 24.1 years (mean) |
Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: results from a randomized clinical trial | Lindström et al. (2003) [18] | Finland | Helsinki, Kuopio, Oulu, Tampere, and Turku | Randomized controlled trial | 522 Control: 257 Intervention: 265 | 172 Control: 81 Intervention: 91 | 350 Control: 176 Intervention: 174 | 40 to 65 years old 55 ± 7 | 3.2 years (mean) |
Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study | Lindström et al. (2006) [19] | Finland | Helsinki, Kuopio, Oulu, Tampere, and Turku | Randomized controlled trial | 522 Control: 257 Intervention: 265 | 172 Control: 31% Intervention: 34% | 350 Control: 69% Intervention: 66% | 40 to 64 years old 55 (mean) | 7 years (median) |
Improved lifestyle and decreased diabetes risk over 13 years: long-term follow-up of the randomized Finnish Diabetes Prevention Study (DPS) | Lindström et al. (2012) [20] | Finland | Helsinki, Kuopio, Oulu, Tampere, and Turku | Randomized controlled trial | 522 Control: 257 Intervention: 265 | 172 | 350 | 40 to 64 years old 55 ± 7 | 0–16 years 9 years (median) |
Reduction in the incidence of type 2 diabetes with the Mediterranean diet: results of the PREDIMED-Reus nutrition intervention randomized trial | Salas-Salvadó et al. (2011) [21] | Spain | Northeastern Spain | Multicenter, randomized, parallel-group primary prevention trial | 418 Control: 134 Intervention group 1: 139 Intervention group 2: 145 | 175 Control: 51 Intervention 1: 56 Intervention 2: 68 | 243 Control: 83 Intervention group 1: 83 Intervention group 2: 77 | 55 to 80 years old Control: 67.8 ± 6.1 Intervention group 1: 67.4 ± 6.1 Intervention group 2: 66.6 ± 5.8 | 4 years (median) |
Delaying progression to type 2 diabetes among high-risk Spanish individuals is feasible in real-life primary healthcare settings using intensive lifestyle intervention | Costa et al. (2012) [22] | Spain | Catalonia | Prospective cohort study | 552 Control: 219 Intervention: 333 | 184 Control: 78 Intervention: 106 | 368 Control: 141 Intervention: 227 | 45 to 75 years old Control: 62.0 ± 7.9 Intervention group: 62.2 ± 8.0 | 3.8 years (mean) 4.2 years (median) |
Prevention of diabetes with Mediterranean diets: a subgroup analysis of a randomized trial | Salas-Salvadó et al. (2014) [23] | Spain | N/A | Parallel-group, randomized, primary cardiovascular prevention trial | 3541 Control: 1147 Intervention group 1: 1154 Intervention group 2: 1240 | 1346 Control: 401 Intervention group 1: 439 Intervention group 2: 5,061,346 | 2195 Control: 746 Intervention group 1: 715 Intervention group 2: 734 | 55 to 80 years old Control: 66.5 ± 6.0 Intervention group 1: 66.2 ± 6.0 Intervention group 2: 67.2 ± 6.1 | 4.1 years (median) |
Effective translation of a type-2 diabetes primary prevention program into routine primary care: the PreDE cluster randomized clinical trial | Sanchez et al. (2018) [24] | Spain | The Basque country | Phase IV randomized cluster clinical trial | 1088 Control: 634 Intervention: 454 | 418 Control: 266 Intervention: 152 | 670 Control: 368 Intervention: 302 | 45 to 70 years old 59.3 ± 6.9 | 2 years |
Quality and quantity of protein intake influence incidence of type 2 diabetes mellitus in coronary heart disease patients: from the CORDIOPREV study | de la Cruz-Ares et al. (2021) [25] | Spain | Córdoba | Randomized, single-blind, controlled intervention trial | 436 Control: 218 Intervention: 218 | 369 Control: 182 Intervention: 187 | 67 Control: 36 Intervention: 31 | 20 to 76 years old Control: 57.4 ± 0.6 Intervention: 58.1 ± 0.6 | 5 years (median) |
Prevention of type 2 diabetes in adults with impaired glucose tolerance: the European Diabetes Prevention RCT in Newcastle upon Tyne, UK | Penn et al. (2009) [26] | UK | Newcastle upon Tyne | Randomized controlled trial | 102 Control: 51 Intervention: 51 | 41 Control: 20 Intervention: 21 | 61 Control: 31 Intervention: 30 | 38 to 74 years old Control: 57.4 Intervention group: 56.8 | 0–5 years 3.1 years (mean) |
Effect of a lifestyle intervention on weight change in south Asian individuals in the UK at high risk of type 2 diabetes: a family-cluster randomized controlled trial | Bhopal et al. (2014) [27] | UK | Edinburgh or Glasgow (Scotland) | Non-blinded, family-cluster randomized controlled trial | 171 Control: 86 Intervention: 85 | 78 Control: 39 Intervention: 39 | 93 Control: 46 Intervention: 47 | 35 to 80 years old Control: 52.2 ± 10.3 Intervention group: 52.8 ± 10.2 | 3 years |
A community-based primary prevention program for type 2 diabetes integrating identification and lifestyle intervention for prevention: the Let’s Prevent Diabetes cluster randomized controlled trial | Davies et al. (2016) [28] | UK | Leicestershire | Cluster randomized controlled trial | 880 Control: 433 Intervention: 447 | 560 Control: 278 Intervention: 282 | 320 Control: 155 Intervention: 165 | 40–75 if White European; 25–75 years if South Asian Control: 63.9 ± 7.9 Intervention group: 63.9 ± 7.6 | 3 years (median) |
A pragmatic and scalable strategy using mobile technology to promote sustained lifestyle changes to prevent type 2 diabetes in India and the UK: a randomized controlled trial | Nanditha et al. (2020) [29] | UK | N/A | Randomized controlled trial | 891 Control: 444 Intervention: 447 | 432 Control: 216 Intervention: 216 | 459 Control: 228 Intervention: 231 | 40 to 74 years old Control: 60.2 ± 9.3 Intervention group: 60.3 ± 9.4 | 2 years |
Lifestyle intervention with or without lay volunteers to prevent type 2 diabetes in people with impaired fasting glucose and/or nondiabetic hyperglycemia: a randomized clinical trial | Sampson et al. (2021) [30] | UK | East of England | Randomized clinical 3-arm parallel-group trial | 1028 Control: 178 Intervention group 1: 424 Intervention group 2: 426 | 645 Control: 108 Intervention group 1: 258 Intervention group 2: 279 | 383 Control: 70 Intervention group 1: 166 Intervention group 2: 147 | Above 40 years old Control: 65.3 ± 10 Intervention group 1: 66.5 ± 8.6 Intervention group 2: 66.7 ± 9.5 | 3.8 years 2 years (mean) |
Predictors of lifestyle intervention outcome and dropout: the SLIM study | Roumen et al. (2011) [31] | The Netherlands | Maastricht | Randomized controlled trial | 147 Control: 73 Intervention: 74 | 75 Control: 37 Intervention: 38 | 72 Control: 36 Intervention: 36 | Control: 58.8 ± 8.4 Intervention group: 55.0 ± 6.5 | 3–6 years 4.1 years (mean) |
A lifestyle intervention to reduce Type 2 diabetes risk in Dutch primary care: 2.5-year results of a randomized controlled trial | Vermunt et al. (2012) [32] | The Netherlands | Eindhoven and surrounding | Randomized controlled trial | 925 Control: 446 Intervention: 479 | N/A | N/A | 40 to 70 years old | 2.5 years |
References | Q1 | Q2 * | Q3 | Q4 | Q5 | Q6 * | Q7 | Q8 | Q9 * | Q10 | Q11 * | Q12 | Q13 | Q14 | Quality |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Skaaby et al. [17] | Y | NR | N | NA | NR | Y | CD | CD | NR | NR | NR | NR | Y | Y | L |
Lindström et al. [20] | Y | NR | N | NA | N | Y | N | Y | Y | NA | Y | N | Y | Y | L |
de la Cruz-Ares et al. [25] | Y | Y | NR | NA | N | Y | NR | NR | NR | NR | Y | NR | N | Y | L |
Vermunt et al. [32] | Y | N | NR | NA | N | Y | N | Y | NR | NR | Y | Y | Y | NR | L |
Sanchez et al. [24] | Y | Y | N | NA | Y | Y | Y | Y | NR | Y | Y | Y | Y | Y | M |
Sampson et al. [30] | Y | Y | Y | NA | NR | Y | N | N | NR | Y | Y | Y | Y | Y | L |
Salas-Salvadó et al. [23] | Y | Y | Y | NA | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | H |
Salas-Salvadó et al. [21] | Y | NR | NR | NA | Y | Y | CD | CD | Y | Y | Y | NR | Y | Y | L |
Roumen et al. [31] | Y | NR | NR | NA | NR | Y | N | Y | N | N | CD | CD | Y | Y | L |
Penn et al. [26] | Y | Y | Y | NA | N | N | Y | N | CD | CD | Y | N | Y | Y | L |
Nanditha et al. [29] | Y | Y | Y | NA | Y | Y | CD | CD | Y | NR | Y | CD | Y | Y | L |
Lindström et al. [19] | Y | NR | NR | NA | NR | Y | Y | Y | N | NR | Y | CD | Y | Y | L |
Lindström et al. [18] | Y | NR | NR | NA | NR | Y | Y | NR | CD | NR | CD | NR | Y | Y | L |
Davies et al. [28] | Y | Y | Y | NA | CD | N | N | Y | CD | CD | Y | CD | Y | Y | L |
Costa et al. [22] | N | NA | N | NA | CD | Y | N | Y | CD | N | Y | Y | CD | Y | L |
Bhopal et al. [27] | Y | Y | Y | NA | N | Y | Y | Y | N | CD | Y | Y | Y | Y | M |
Author (Year) | Ethical Approval | Ethical Approval Details | Type 2 Diabetes Diagnosis | Comorbidity | Population Characteristics |
---|---|---|---|---|---|
Skaaby et al. (2018) [17] | Yes | The study was conducted according to the Helsinki Declaration and Danish relevant ethics committees. All participants gave their written and informed consent. | Hospitalization with a diagnosis of diabetes; measurements of blood glucose either five times or more within 1 year; two or more annual measurements during a 5-year period; registered use of chiropody (coded for diabetes); prescription of oral antidiabetic medication or insulin at least twice | Not reported | Danish people age 30–60 without type 2 diabetes from 11 municipalities in the suburbs of Copenhagen |
Lindström et al. (2003) [18] | Yes | The ethics committee of the National Public Health Institute in Helsinki, Finland, approved the study protocol. All study participants gave written informed consent. | Defined according to the WHO 1985 criteria [34], i.e., either a fasting plasma glucose concentration over 140 mg/dL or 2 h post-challenge plasma glucose concentration of 200 mg/dL | Overweight subjects, body mass index (BMI) > 25 kg/m2 and with IGT | Finnish overweight subjects, body mass index (BMI) > 25 kg/m2 with IGT aged 40 to 65 years |
Lindström et al. (2006) [19] | Yes | The ethics committee of the National Public Health Institute in Helsinki, Finland, approved the study protocol. All study participants gave written informed consent. | Diabetes was defined according to WHO 1985 criteria, i.e., either fasting plasma glucose of 7.8 mmol/L or more or 2 h post-challenge plasma glucose of 11.1 mmol/L or more | Overweight, middle-aged men and women with impaired glucose tolerance | Overweight (mean body mass index 31.1 kg/m2), middle-aged (mean age 55 years) participants with impaired glucose tolerance |
Lindström et al. (2012) [20] | Yes | The ethics committees of the National Public Health Institute in Helsinki, Finland (intervention phase), and of the North Ostrobothnia Hospital District (follow-up period) approved the study protocol. All study participants gave written informed consent at baseline and again at the beginning of the post- intervention follow-up | Fasting plasma glucose ≥ 7.8 mmol/L or 2 h plasma glucose ≥ 11.1 mmol/L in two separate OGTTs (WHO 1985 criteria) | Overweight, middle-aged persons with impaired glucose tolerance | European population aged between 40 and 64, overweight persons with impaired glucose tolerance |
Salas-Salvadó et al. (2011) [21] | Yes | The local institutional review board approved the study protocol. All participants provided written informed consent. | American Diabetes Association criteria: fasting plasma glucose > 7.0 mmol/L or 2 h plasma glucose > 11.1 mmol/L after a 75 g oral glucose load, measured yearly | At least three cardiovascular risk factors, namely smoking, hypertension, dyslipidemia, overweightness (BMI ≥ 25 kg/m2), and family history of premature cardiovascular disease (55 years in men and 60 years in women) | Community-dwelling men and women without prior cardiovascular disease but with at least three cardiovascular risk factors and family history of premature cardiovascular disease |
Costa et al. (2012) [22] | Yes | The research ethics committee board at the Jordi Gol Research Institute (Barcelona, Spain) approved the study protocol. All participants gave written informed consent. | OGTT > 11.1 mmol/L (WHO criteria) | FINDRISC score >14 or prediabetes defined using WHO criteria for fasting or 2 h glucose | White European individuals without diabetes aged 45–75 years |
Salas-Salvadó et al. (2014) [23] | Yes | The institutional review board (IRB) of Hospital Clinic (Barcelona, Spain) approved the study protocol. All participants provided written informed consent. | American Diabetes Association (ADA) criteria: fasting plasma glucose levels of 7.0 mmol/L or greater (126.1 mg/dL) or 2 h plasma glucose levels of 11.1 mmol/L or greater (200.0 mg/dL) after a 75 g oral glucose load | Community-dwelling men and women without CVD at baseline who had either type 2 diabetes or at least three or more cardiovascular risk factors, namely current smoking, hypertension, hypercholesterolemia, low high-density lipoprotein cholesterol levels, overweightness or obesity, and family history of premature CVD | Spanish men and women without diabetes at high cardiovascular risk |
Sanchez et al. (2018) [24] | Yes | The Basque Country Clinical Research Ethics Committee approved the study protocol. All participants received the patient information sheet and gave written consent. | Assessed by the OGTT in accordance with the WHO protocol and a cut-off point for type 2 diabetes diagnosis ≥ 200 mg/mL | Attendees considered at high risk of T2D (FINDRISC ≥ 14 points) | Spanish nondiabetic 45 to 70-year-old primary health care attendees considered at high risk of type 2 diabetes (FINDRISC ≥ 14 points) |
de la Cruz-Ares et al. (2021) [25] | Yes | The local ethics committees, the Helsinki Declaration, and Good Clinical Practice guidelines approved the trial protocol. All participants gave written informed consent to participate in the study. | Fasting glucose ≥ 126 mg/dL, 2 h glucose during OGTT ≥ 200 mg/dL, or HbA1c ≥ 6.5% (ADA criteria for diagnosis of type 2 diabetes) | Coronary heart disease patients of European ancestry who had their last coronary event more than 6 months before enrollment | Coronary heart disease patients of European ancestry who had their last coronary event more than 6 months before enrollment |
Penn et al. (2009) [26] | Yes | The Newcastle and North Tyneside NHS Research Ethics Committee approved the study protocol. All participants gave informed, written consent before the start of the study. | Derived from the mean of two standard oral glucose tolerance tests (OGTTs)—stratum 1: 7.8 to 9.4 mmol/L; stratum 2: 9.5 to 11.1 mmol/L) | Impaired glucose tolerance | Participants from the UK, aged between 38 and 74 |
Bhopal et al. (2014) [27] | Yes | The Scotland A Research Ethics Committee approved the study. Outcomes were reviewed annually by a data monitoring and ethics committee. | 75 g oral glucose tolerance test. The oral glucose tolerance test followed standardized procedures, with venous blood taken after an overnight fast of 10–16 h and 2 h after glucose load | Impaired glucose tolerance or impaired fasting glucose | Individuals of south Asian descent living in the UK |
Davies et al. (2016) [28] | Yes | Ethical approval was sought, and the study involved practice-level and individual-level informed consent. | WHO 1999 [34] criteria/guidelines. Following the update of the WHO diagnostic criteria to include HbA1c (WHO, 2011) [35], we obtained a protocol amendment in January 2013, allowing HbA1c ≥ 6.5% to become part of the diagnostic criteria for T2DM within this study | people at risk of PDM/T2DM | people with prediabetes mellitus |
Nanditha et al. (2020) [29] | Yes | In the UK, approval was from the Westminster Research Ethics Committee and site specific assessment (SSA) plus research and development (R&D) approvals were in place at each participating NHS Trust. | Diabetes as defined by international criteria for fasting plasma glucose or HbA1c at any study review visit or in any healthcare setting | People with prediabetes defined by an HbA1c level of ≥42 and ≤47 mmol/mol (≥6.0% and ≤6.4% | People who met the HbA1c entry criteria (≥42 and ≤47 mmol/mol [≥6.0% and ≤6.4%]) |
Sampson et al. (2021) [30] | Yes | The National Research Ethics Service research ethics committee approved the study. All participants gave written informed consent. | Paired fasting glucose measurements both ≥ 7.0 mmol/L, or a 2 h OGTT ≥ 11.1 mmol/L undertaken if HbA1c ≥ 42 mmol/L in IFG participants (WHO criteria) | People at increased risk of type 2 diabetes: elevated fasting plasma glucose level alone or an elevated glycated hemoglobin level with an elevated fasting plasma glucose level/people with current prediabetes glycemic categories | People with nondiabetic hyperglycemia |
Roumen et al. (2011) [31] | Yes | The Medical Ethics Review Committee of Maastricht University approved the study protocol. All subjects gave written informed consent before the start of the study. | The incidence of type 2 diabetes was determined according to the World Health Organization criteria of 1999 | Impaired glucose tolerance | Dutch population with impaired glucose tolerance (IGT) |
Vermunt et al. (2012) [32] | Yes | The Medical Ethical Review Committee of the Catharina Hospital in Eindhoven, the Netherlands, approved the study. | Diagnosis of type 2 diabetes was based on one oral glucose tolerance test according to the 2006 World Health Organization diagnostic criteria | Participants with FINDRISC score ≥ 13 (higher risk of developing type 2 diabetes) | European, aged between 40 and 70 |
Title | Author (Year) | Country | Intervention | Number of Cases (n) | Value of the Outcome Measure (Control) | Value of the Outcome Measure (Intervention) | Interpretation |
---|---|---|---|---|---|---|---|
A randomized general population study of the effects of repeated health checks on incident diabetes | Skaaby et al. (2018) [17] | Denmark | Repeated general health checks. Personalized feedback and counseling based on their health assessments. | 2636 | HR: 1.07 (95% CI: 0.98–1.16, p = 0.153) | Repeated general health checks with personalized feedback and counseling showed no beneficial and significant intervention effect on the development of diabetes. | |
Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: results from a randomized clinical trial | Lindström et al. (2003) [18] | Finland | Modifying eating behavior. Seven sessions with a nutritionist during the first year of the study and every 3 mo thereafter. Individually tailored circuit-type resistance training sessions. | Control: 59 Intervention: 27 | Cumulative incidence percentage (Year 1): 6.1 (95% CI: 3.2–9.0) Cumulative incidence percentage (Year 2): 14.4 (95% CI: 9.9 to 18.6) Cumulative incidence percentage (Year 3): 20.9 (95% CI: 15.5 to 25.9) Cumulative incidence percentage (Year 4): 23.0 (95% CI: 16.9 to 28.6) Cumulative incidence percentage (Year 5): 34.4 (95% CI: 21.9 to 44.9) Cumulative incidence percentage (Year 6): 42.6 (95% CI: 26.0 to 55.5) | Cumulative incidence percentage (Year 1): 1.9 (95% CI: 0.2 to 3.6) Cumulative incidence percentage (Year 2): 6.3 (95% CI: 3.2 to 9.2) Cumulative incidence percentage (Year 3): 9.1 (95% CI: 5.4 to 12.6) Cumulative incidence percentage (Year 4): 10.9 (95% CI: 6.4 to 15.2) Cumulative incidence percentage (Year 5): 20.0 (95% CI: 8.8 to 29.8) Cumulative incidence percentage (Year 6): 20.0 (95% CI: 8.8 to 29.8) | The risk of diabetes was reduced by a statistically significant 58% in the intervention group compared to the control. |
HR: 0.4 (95% CI: 0.3–0.7, p < 0.001) | |||||||
Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study | Lindström et al. (2006) [19] | Finland | Intensive diet-exercise counseling. Detailed and individualized counseling to achieve the lifestyle goals. Individually tailored circuit-type moderate-intensity resistance training sessions. | Control: 110 Intervention: 75 | Incidence rate per 100 person-years: 7.4 (95% CI: 6.1–8.9, p = 0.001) | Incidence rate per 100 person-years: 4.3 (95% CI: 3.4–5.4, p = 0.001) | The overall incidence of diabetes was reduced by a statistically significant 43% in the intervention group compared to the control. |
HR: 0.57 (95% CI: 0.43–0.76, p = 0.001) | |||||||
Improved lifestyle and decreased diabetes risk over 13 years: long-term follow-up of the randomized Finnish Diabetes Prevention Study (DPS) | Lindström et al. (2012) [20] | Finland | Individualized lifestyle intervention. Counseling sessions with nutritionist. Supervised exercise sessions in the gym. | Control: 140 Intervention: 106 | Incidence rate per 100 person-years (control): 7.2 (95% CI 6.1–8.5) Incidence rate per 100 person-years (intervention): 4.5 (95% CI 3.8–5.5) HR: 0.614 (95% CI: 0.478–0.789, p < 0.001) | Absolute risk of developing type 2 diabetes was reduced by a statistically significant 19.4% in the intervention group compared to the control. | |
Reduction in the incidence of type 2 diabetes with the Mediterranean diet: results of the PREDIMED-Reus nutrition intervention randomized trial | Salas-Salvadó et al. (2011) [21] | Spain | Behavioral intervention promoting the MedDiet. Allocated diet (low-fat or Med diet). | Control: 24 Intervention group 1: 14 Intervention group 2: 16 | Incidence rate per 1000 person-years: 46.4 (95% CI: 30.1–68.5) Cumulative incidence rate: 17.9 (95% CI: 11.4–24.2) | Incidence rate per 1000 person-years (MedDiet + VOO): 24.6 (95% CI: 13.5–40.8) Incidence rate per 1000 person-years (MedDiet + Nuts): 26.8 (95% CI: 15.3–43.0) Cumulative incidence rate (MedDiet + VOO): 10.1 (95% CI: 5.1–15.1) Cumulative incidence rate (MedDiet + Nuts): 11.0 (95% CI: 5.9–16.1) | Following a median follow-up of 4.0 years, diabetes rates were reduced by a statistically significant 51% and 52% with the consumption of a Mediterranean diet supplemented with virgin olive oil or mixed nuts, respectively, compared to the control diet group. |
HR crude (MedDiet + VOO vs. Con): 0.53 (95% CI: 0.27–1.09) HR crude (MedDiet + Nuts vs. Con): 0.58 (95% CI: 0.31–1.10) HR crude (Combined MedDiet vs. Con): 0.55 (95% CI: 0.32–0.95) HR age- and sex-adjusted (MedDiet + VOO vs. Con): 0.52 (95% CI: 0.27–1.00) HR age- and sex-adjusted (MedDiet + Nuts vs. Con): 0.55 (95% CI: 0.29–1.00) HR age- and sex-adjusted (Combined MedDiet vs. Con): 0.53 (95% CI: 0.31–0.92) HR multivariate-adjusted (MedDiet + VOO vs. Con): 0.49 (95% CI: 0.25–0.97) HR multivariate-adjusted (MedDiet + Nuts vs. Con): 0.48 (95% CI: 0.24–0.96) HR multivariate-adjusted (Combined MedDiet vs. Con): 0.48 (95% CI: 0.27–0.86) | |||||||
Delaying progression to type 2 diabetes among high-risk Spanish individuals is feasible in real-life primary healthcare settings using intensive lifestyle intervention | Costa et al. (2012) [22] | Spain | A 6 h educational program scheduled in two to four sessions. Increase knowledge of type 2 diabetes risks. Promote the Mediterranean diet and provide nutritional advice. Increase adherence to the Mediterranean diet. | Control: 63 Intervention: 61 | HR: 0.54 (95% CI: 0.37–0.79) | The risk of diabetes was reduced by a statistically significant 46% in the intervention group compared to the control. | |
Incidence percentage: 22.8% (95% CI: 22.9–35.3%) | Incidence percentage: 18.3% (95% CI: 14.3–22.9%) | ||||||
HR: 0.64 (95% CI: 0.47–0.87, p < 0.004) | |||||||
Prevention of diabetes with Mediterranean diets: a subgroup analysis of a randomized trial | Salas-Salvadó et al. (2014) [23] | Spain | Behavioral intervention promoting the Mediterranean diet. Allocated diet (low-fat or Med diet). | Control: 101 Intervention group 1: 80 Intervention group 2: 92 | Incidence rate per 1000 person-years: 23.6 (95% CI: 19.3–28.7) Cumulative incidence: 8.81 (95% CI: 7.23–10.60) | Incidence rate per 1000 person-years (MedDiet + EVOO): 16 (95% CI: 12.7–19.9) Cumulative incidence (MedDiet + EVOO): 6.93 (95% CI: 5.53–8.55) Incidence rate per 1000 person-years (MedDiet + Nuts): 18.7 (95% CI: 15.1–22.9) Cumulative incidence (MedDiet + Nuts): 7.42 (95% CI: 6.02–9.02) | Following a median follow-up of 4.1 years, the Mediterranean diet groups supplemented with extra-virgin olive oil and mixed nuts showed a statistically significant 40% relative risk reduction and a nonsignificant 18% risk reduction in diabetes risk, respectively, compared to the control diet group. |
HR crude (MedDiet + EVOO vs. Con): 0.69 (95% CI: 0.51–0.92) HR crude (MedDiet + Nuts vs. Con): 0.81 (95% CI: 0.61–1.08) HR crude (Combined MedDiet vs. Con): 0.75 (95% CI: 0.58–0.96) HR age- and sex-adjusted (MedDiet + EVOO vs. Con): 0.68 (95% CI: 0.51–0.92) HR age- and sex-adjusted (MedDiet + Nuts vs. Con): 0.80 (95% CI: 0.60–1.06) HR age- and sex-adjusted (Combined MedDiet vs. Con): 0.74 (95% CI: 0.58–0.95) HR multivariate-adjusted A (MedDiet + EVOO vs. Con): 0.68 (95% CI: 0.51–0.92) HR multivariate-adjusted A (MedDiet + Nuts vs. Con): 0.82 (95% CI: 0.61–1.09) HR multivariate-adjusted A (Combined MedDiet vs. Con): 0.75 (95% CI: 0.58–0.96) HR multivariate-adjusted B (MedDiet + EVOO vs. Con): 0.60 (95% CI: 0.43–0.85) HR multivariate-adjusted B (MedDiet + Nuts vs. Con): 0.82 (95% CI: (0.61–1.10) HR multivariate-adjusted B (Combined MedDiet vs. Con): 0.70 (95% CI: 0.54–0.92) | |||||||
Effective translation of a type-2 diabetes primary prevention program into routine primary care: the PreDE cluster randomized clinical trial | Sanchez et al. (2018) [24] | Spain | Educational sessions to promote healthy lifestyle and provide information concerning diets and exercise. Continuous reinforcement through regular contact via telephone calls from nurses. | Control: 77 Intervention: 38 | Unadjusted RR (intention to treat): 0.68 (95% CI: 0.47–0.99, p = 0.048) Unadjusted RR (per protocol): 0.69 (95% CI: 0.47–1.00) Adjusted RR (intention to treat): 0.68 (95% CI: 0.49–0.95) Adjusted RR (per protocol): 0.56 (95% CI: 0.39–0.81) | Relative risk of type 2 diabetes was reduced by a statistically significant 32% in the intervention group compared to the control. | |
Quality and quantity of protein intake influence incidence of type 2 diabetes mellitus in coronary heart disease patients: from the CORDIOPREV study | de la Cruz-Ares et al. (2021) [25] | Spain | Modifying eating behavior. Allocated diet (low-fat or Med diet). | 106 | HR unadjusted model: 0.6008 (95% CI: 0.4064–0.8883, p = 0.0096) HR multivariable model 1: 0.5981 (95% CI: 0.4043–0.8848, p = 0.0199) HR multivariable model 2: 0.6385 (95% CI: 0.4257–0.9578, p = 0.0024) | Adopting a diet with more plant-based proteins was linked to a statistically significant 36% lower risk of developing type 2 diabetes in the intervention group compared to the control. | |
Prevention of type 2 diabetes in adults with impaired glucose tolerance: the European Diabetes Prevention RCT in Newcastle upon Tyne, UK | Penn et al. (2009) [26] | UK | Individual and group activities by dietitian and physiotherapist. Information pack detailing facilities and opportunities for physical activity in Newcastle upon Tyne with a City Card and the opportunity to meet with a trainer at a local leisure center. | Control: 11 Intervention: 5 | Incidence rate per 1000 person-years: 67.1 (95% CI: 34.2–117.5) | Incidence rate per 1000 person-years: 32.7 (95% CI: 10.7–74.6) | The overall incidence of diabetes was reduced by a nonsignificant 55% in the intervention group compared to the control. |
RR: 0.45 (95% CI: 0.2–1.2) | |||||||
Effect of a lifestyle intervention on weight change in south Asian individuals in the UK at high risk of type 2 diabetes: a family-cluster randomized controlled trial | Bhopal et al. (2014) [27] | UK | Families had 15 visits from a dietitian over 3 years. Promoting a calorie-deficit diet and physical activity was emphasized. Advice included information on shopping and cooking. | Control: 17 Intervention: 12 | OR adjusted: 0.68 (95% CI: 0.27–1.67, p = 0.3705) | The intervention group showed a lower frequency of progression to diabetes compared to the control group, though this difference was not statistically significant. | |
A community based primary prevention program for type 2 diabetes integrating identification and lifestyle intervention for prevention: the Let’s Prevent Diabetes cluster randomized controlled trial | Davies et al. (2016) [28] | UK | Increase knowledge and promote realistic perceptions of PDM, as well as promoting healthy behavior and physical activity. Modifying eating behavior. | Control: 67 Intervention: 64 | Incidence rate per 1000 person-years (intention to treat and per protocol): 63.16 (95% CI: 49.71–80.24) | Incidence rate per 1000 person-years (intention to treat): 57.60 (95% CI: 45.09–73.59) Incidence rate per 1000 person-years (per protocol): 53.04 (95% CI: 40.31–69.80) | In the intervention group, there was a 26% reduction in the risk of developing type 2 diabetes compared to the control group, although this reduction was not statistically significant. |
HR: 0.74 (95% CI: 0.48–1.14, p = 0.18) | |||||||
A pragmatic and scalable strategy using mobile technology to promote sustained lifestyle changes to prevent type 2 diabetes in India and the UK: a randomized controlled trial | Nanditha et al. (2020) [29] | UK | Personalized education and motivation about healthy diet and the benefits of enhanced physical activity. Regular short message service (SMS) messages about lifestyle 2–3 times weekly during the trial. | Control: 56 Intervention: 64 | HR: 0.99 (95% CI: 0.69–1.43) | Personalized education and motivation on healthy diet and physical activity, supported by SMS messages 2–3 times a week, resulted in a nonsignificant reduction in diabetes progression in the intervention group over two years. | |
Lifestyle intervention with or without lay volunteers to prevent type 2 diabetes in people with impaired fasting glucose and/or nondiabetic hyperglycemia: a randomized clinical trial | Sampson et al. (2021) [30] | UK | Support maintenance of changes in physical activity and diet using patient-centered counseling techniques. Behavior changes and increased motivation with individually tailored goal settings. | Control: 39 Intervention group 1: 55 Intervention group 2: 62 | OR unadjusted (INT vs. CON): 0.53 (95% CI: 0.34–0.84, p = 0.01) OR unadjusted (INT-DPM vs. CON): 0.60 (95% CI: 0.3–0.93, p = 0.02) OR unadjusted (Combined INT vs. CON): 0.57 (95% CI: 0.38–0.85, p = 0.01) OR adjusted (INT vs. CON): 0.54 (95% CI: 0.34–0.85, p = 0.01) OR adjusted (INT-DPM vs. CON): 0.60 (95% CI: 0.38–0.94, p = 0.02) OR adjusted (Combined INT vs. CON): 0.57 (95% CI: 0.38–0.85, p = 0.01) OR adjusted (INT vs. CON): 0.54 (95% CI: 0.34–0.85, p = 0.01) OR adjusted (INT-DPM vs. CON): 0.61 (95% CI: 0.39–0.96, p = 0.03) OR adjusted (Combined INT vs. CON): 0.57 (95% CI: 0.38–0.87, p = 0.01) | OR unadjusted (INT-DPM vs. INT): 1.11 (95% CI: 0.7–1.65, p = 0.59) OR adjusted (INT-DPM vs. INT): 1.12 (95% CI: 0.75–1.65, p = 0.59) OR adjusted (INT-DPM vs. INT): 1.14 (95% CI: 0.77–1.70, p = 0.51) | Individuals classified in the high-risk intermediate glycemic category with impaired fasting glucose and/or nondiabetic hyperglycemia were 40% to 47% less likely to develop type 2 diabetes in the intervention groups compared to the control over an average period of 24 months. |
HR unadjusted (INT vs. CON): 0.53 (95% CI: 0.35–0.80, p = 0.003) HR unadjusted (INT-DPM vs. CON): 0.62 (95% CI: 0.41–0.92, p = 0.02) HR unadjusted (Combined INT vs. CON): 0.57 (95% CI: 0.40–0.82, p = 0.002) HR adjusted (INT vs. CON): 0.53 (95% CI: 0.35–0.81, p = 0.003) HR adjusted (INT-DPM vs. CON): 0.64 (95% CI: 0.43–0.97, p = 0.03) HR adjusted (Combined INT vs. CON): 0.58 (95% CI: 0.41–0.84, p = 0.004) | HR unadjusted (INT-DPM vs. INT): 1.09 (95% CI: 0.76–1.57, p = 0.63) HR adjusted (INT-DPM vs. INT): 1.13 (95% CI: 0.78–1.63, p = 0.51) | ||||||
Predictors of lifestyle intervention outcome and dropout: the SLIM study | Roumen et al. (2011) [31] | The Netherlands | Dietary recommendations and physical activity training. Personalized advice from researcher and/or dietitian. | N/A | RR: 0.53 (95% CI: 0.29–0.97, p = 0.04) | Lifestyle counseling was associated with a statistically significant diabetes risk reduction of 47% in the intervention group compared to the control. | |
A lifestyle intervention to reduce type 2 diabetes risk in Dutch primary care: 2.5-year results of a randomized controlled trial | Vermunt et al. (2012) [32] | The Netherlands | Consultations with the nurse practitioner and the general practitioner. Meetings with dieticians and physiotherapists to provide information on diet and exercise. | Control: 46 Intervention: 41 | Cumulative incidence percentage (p = 0.14): 0.5 year: 3.9% 1.5 year:8.3% 2.5 year: 11.9% | Cumulative incidence percentage (p = 0.28): 0.5 year: 4.6% 1.5 year:8.1% 2.5 year: 10% | Cumulative diabetes incidence was not significantly different between the intervention and the usual care (control) group. |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Andrade, C.A.S.; Lovas, S.; Mahrouseh, N.; Chamouni, G.; Shahin, B.; Mustafa, E.O.A.; Muhlis, A.N.A.; Njuguna, D.W.; Israel, F.E.A.; Gammoh, N.; et al. Primary Prevention of Type 2 Diabetes Mellitus in the European Union: A Systematic Review of Interventional Studies. Nutrients 2025, 17, 1053. https://doi.org/10.3390/nu17061053
Andrade CAS, Lovas S, Mahrouseh N, Chamouni G, Shahin B, Mustafa EOA, Muhlis ANA, Njuguna DW, Israel FEA, Gammoh N, et al. Primary Prevention of Type 2 Diabetes Mellitus in the European Union: A Systematic Review of Interventional Studies. Nutrients. 2025; 17(6):1053. https://doi.org/10.3390/nu17061053
Chicago/Turabian StyleAndrade, Carlos Alexandre Soares, Szabolcs Lovas, Nour Mahrouseh, Ghenwa Chamouni, Balqees Shahin, Eltayeb Omaima Awad Mustafa, Abdu Nafan Aisul Muhlis, Diana Wangeshi Njuguna, Frederico Epalanga Albano Israel, Nasser Gammoh, and et al. 2025. "Primary Prevention of Type 2 Diabetes Mellitus in the European Union: A Systematic Review of Interventional Studies" Nutrients 17, no. 6: 1053. https://doi.org/10.3390/nu17061053
APA StyleAndrade, C. A. S., Lovas, S., Mahrouseh, N., Chamouni, G., Shahin, B., Mustafa, E. O. A., Muhlis, A. N. A., Njuguna, D. W., Israel, F. E. A., Gammoh, N., Chandrika, N., Atuhaire, N. C., Ashkar, I., Chatterjee, A., Charles, R., Alzuhaily, H., Almusfy, A., Díaz Benavides, D., Alshakhshir, F. K., & Varga, O. (2025). Primary Prevention of Type 2 Diabetes Mellitus in the European Union: A Systematic Review of Interventional Studies. Nutrients, 17(6), 1053. https://doi.org/10.3390/nu17061053